CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-1 LIGAND-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A 5-YEAR-FOLLOW-UP STUDY

被引：0
|
作者：
Chen, Y-B [1 ]
Mu, C-Y [1 ]
Huang, J-A [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Resp Med, Suzhou, Peoples R China
来源：
RESPIROLOGY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [41] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
    Liang, Jiaqi
    Li, Ming
    Sui, Qihai
    Hu, Zhengyang
    Bian, Yunyi
    Huang, Yiwei
    Zhan, Cheng
    Jiang, Wei
    Wang, Qun
    Tan, Lijie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
  • [42] Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mino-Kenudson, Mari
    CANCER BIOLOGY & MEDICINE, 2016, 13 (02) : 157 - 170
  • [43] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Artem
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2016, 96 : 467A - 467A
  • [44] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, 13 (02) : 157 - 170
  • [45] Programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer (NSCLC), results of a single institution
    Slezak, A.
    Toth, E.
    VIRCHOWS ARCHIV, 2018, 473 : S112 - S112
  • [46] The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
    Skov, Birgit Guldhammer
    Rorvig, Sara Bird
    Jensen, Thomas Hartvig Lindkaer
    Skov, Torsten
    MODERN PATHOLOGY, 2020, 33 (01) : 109 - 117
  • [47] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Arteni
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    MODERN PATHOLOGY, 2016, 29 : 467A - 467A
  • [48] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, (02) : 157 - 170
  • [49] Programmed Death Ligand-1 (PD-L1) Expression in Patients with Non-Small Cell Lung Cancer (NSCLC) with Unusual Metastasis: A Case Series
    Tsugitomi, R.
    Nishimura, N.
    Imai, R.
    Okafuji, K.
    Kitamura, A.
    Tomishima, Y.
    Jinta, T.
    Suzuki, K.
    Tamura, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [50] Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India
    Vallonthaiel, Archana George
    Malik, Prabhat Singh
    Singh, Varsha
    Kumar, Vinay
    Kumar, Sunil
    Sharma, Mehar Chand
    Mathur, Sandeep
    Arava, Sudheer
    Guleria, Randeep
    Jain, Deepali
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 31 : 56 - 61
12345